FUNDING
Company Profile
Flare Therapeutics is a clinical-stage biotech developing small-molecule drugs that target transcription factors, including a first-in-class ARON-targeting degrader for prostate cancer.
Founded 2021Cambridge, Massachusetts$290M raised
Investors
Third Rock VenturesNextech InvestPfizer VenturesBoxer CapitalGordonMD Global InvestmentsInvusCasdin CapitalEli Lilly and Company
Compare with
Funding & Valuation History
from our coverage| Date | Event | Amount | Valuation | Source |
|---|---|---|---|---|
| Jun 30, 2026 | Flare Therapeutics Raises $85M, Names New CEO | $85M Series C | — | Story → |
Flare Therapeutics FAQ
- How much has Flare Therapeutics raised?
- Flare Therapeutics has raised approximately $290M in total funding to date.
- Is Flare Therapeutics publicly traded?
- No. Flare Therapeutics is privately held.
- Who are Flare Therapeutics's investors?
- Flare Therapeutics's investors include Third Rock Ventures, Nextech Invest, Pfizer Ventures, Boxer Capital, GordonMD Global Investments, Invus, Casdin Capital, Eli Lilly and Company.
Coverage Timeline
newest firstAll Coverage
FUNDING$391M+ combined across 3 single-trial bets
Biotech VCs Are Betting Big on Single Clinical Trials
Celea Therapeutics' $180M round, Beeline Medicine's $126.3M raise and Flare Therapeutics' $85M financing show late-stage biotech investors concentrating capital into single, high-conviction trial bets rather than diversified platform plays.
FUNDING
Flare Therapeutics Raises $85M, Names New CEO
FUNDING$85M Series C
Flare Therapeutics Raises $85M, Names New CEO
Flare Therapeutics closed an $85 million insider-led Series C and named Anna Protopapas CEO, funding its first-in-class ARON-targeting degrader for prostate cancer toward a Phase 1A trial expected in Q3 2026.